Curaxin CBL0137 has the potential to reverse HIV-1 latency.
Maxime J JeanDawei ZhouGuillaume FichesWeili KongHuachao HuangAndrei PurmalKaterina GurovaNetty G SantosoJian ZhuPublished in: Journal of medical virology (2019)
A cure for human immunodeficiency virus type-1 (HIV-1) has been hampered by the limitation of current combination antiretroviral therapy (cART) to address the latent reservoirs in HIV-1 patients. One strategy proposed to eradicate these reservoirs is the "shock and kill" approach, where latency-reversing agents (LRAs) are used to reactivate and promote viral cell death and/or immune killing of reactivated cells. Here, we report that curaxin CBL0137, an antitumor compound, can potentiate tumor necrosis factor-α-mediated reactivation of latently infected HIV-1cell lines. Additionally, the single use of CBL0137 is sufficient to reactivate HIV-1 latent reservoirs in peripheral mononuclear cells (PBMCs) isolated from HIV-1 positive, cART-treated, aviremic patients. Thus, CBL0137 possesses capabilities as a LRA and could be considered for the "shock and kill" approach.
Keyphrases
- antiretroviral therapy
- hiv positive
- human immunodeficiency virus
- hiv infected
- hiv aids
- hiv infected patients
- men who have sex with men
- end stage renal disease
- south africa
- hepatitis c virus
- hiv testing
- newly diagnosed
- cell death
- cell cycle arrest
- chronic kidney disease
- ejection fraction
- induced apoptosis
- rheumatoid arthritis
- prognostic factors
- risk assessment
- peritoneal dialysis
- sars cov
- signaling pathway
- endoplasmic reticulum stress